Leprosy Clinical Trial
Official title:
A Phase 1b / 2a, Double-Blind, Randomized, Placebo-Controlled, Antigen Dose-Escalation Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of LEP-F1 + GLA-SE in Adult Participants in Areas Endemic for Leprosy
This is a phase 1b/2a, double-blind, randomized, placebo-controlled clinical trial to evaluate the safety, tolerability, and immunogenicity of the LEP-F1 + GLA-SE investigational vaccine compared to placebo.
The proposed clinical trial will establish an initial safety profile for the vaccine in a region endemic for leprosy. The trial will enroll both healthy participants and paucibacillary leprosy patients receiving standard-of-care therapy. Safety at the lower vaccine dose will be demonstrated in healthy participants prior to antigen dose-escalation. Further, safety in all healthy participants will be demonstrated prior to enrolling leprosy patients. Participants will be randomized within each Group to receive three doses of vaccine or placebo administered IM on Days 0, 28, and 56. Participants will be monitored for one year following the last study injection. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03302897 -
Phase 1 LEP-F1 + GLA-SE Vaccine Trial in Healthy Adult Volunteers
|
Phase 1 | |
Recruiting |
NCT05243654 -
Efficacy and Tolerability of Adjunct Metformin for Multibacillary Leprosy
|
Phase 2 | |
Completed |
NCT05091216 -
The Effects of Traditional Chinese Medicine Mouthwash Solutions on the Oral Health of Leprosy Patients
|
N/A | |
Completed |
NCT00860717 -
The Use of Low Level Laser Therapy for Wound Healing in Leprosy Patients
|
N/A | |
Recruiting |
NCT06222372 -
Novel Interventions and Diagnostic Tests for Leprosy
|
N/A | |
Terminated |
NCT03084614 -
CD8 Reactivity to Microorganisms in Blood and Breast Milk
|
||
Recruiting |
NCT05597280 -
Bedaquiline Enhanced Post ExpOsure Prophylaxis for Leprosy
|
Phase 3 | |
Terminated |
NCT01751503 -
Extramembranous and Interosseous Technique of Tibialis Posterior Tendon Transfer
|
N/A | |
Active, not recruiting |
NCT03324035 -
Treatment of Neuropathic Pain in Leprosy
|
Phase 3 | |
Completed |
NCT03683745 -
Integrated Mapping of Skin-presenting Neglected Tropical Diseases in Liberia
|
||
Recruiting |
NCT02550080 -
Clinical Utility Of Genetic Screening For HLA-B*1301, On Susceptibility To Dapsone Hypersensitivity Syndrome
|
Phase 4 | |
Completed |
NCT02484469 -
Impact of the Virtual Human Project on Team-based Learning: A Randomized-controlled Trial
|
N/A | |
Completed |
NCT01165840 -
Effect of Weight and/or Obesity on Dapsone Drug Concentrations
|
Phase 4 | |
Completed |
NCT00919542 -
Ciclosporin in the Management of New Erythema Nodosum Leprosum
|
Phase 2 | |
Completed |
NCT05406479 -
Bedaquiline Enhanced Post ExpOsure Prophylaxis for Leprosy (Phase 2)
|
Phase 2 | |
Recruiting |
NCT03807362 -
CC-11050 Trial in Nepalese Patients With Erythema Nodosum Leprosum
|
Phase 2 | |
Completed |
NCT01006759 -
Prevention of Disability: Proposal for a Guidance Manual for Leprosy Patients
|
Phase 1 | |
Completed |
NCT03662022 -
Post ExpOsure Prophylaxis for LEprosy in the Comoros and Madagascar
|
Phase 3 | |
Completed |
NCT01920750 -
Leprosy Skin Test Antigens Phase 1
|
Phase 1 | |
Recruiting |
NCT06416033 -
Serum Irisin Level In Leprosy Patients
|